IO colitis is inflammation of the colon triggered by immune checkpoint inhibitor (ICI) therapy, a class of cancer drugs that work by releasing the brakes on your immune system so it can attack tumors. The problem is that an unleashed immune system sometimes turns on healthy tissue too, and the gut is one of the most common targets. Depending on which drug you receive, IO colitis develops in roughly 1 to 14 percent of patients, and it ranges from mild diarrhea that resolves on its own to a life-threatening emergency requiring hospitalization. Understanding how it presents, how doctors grade and diagnose it, and what the treatment ladder looks like can make a real difference in catching it early and managing it well.
Why Immune Checkpoint Inhibitors Cause Gut Inflammation
Checkpoint inhibitors block proteins like CTLA-4, PD-1, or PD-L1 that normally keep immune cells from overreacting. When those checkpoints are removed, T cells become more aggressive against cancer cells, but they can also start attacking the lining of your colon. Research in animal models and human tissue has shown that this inflammation is driven by highly active immune cells that flood the gut wall. A study in Nature Communications found that the strongest molecular signal in IO colitis is a surge in the interferon-gamma pathway, alongside activation of T cell signaling, dendritic cell maturation, and genes involved in cell-mediated killing. The colonic tissue also showed disrupted genes related to the epithelial barrier, some of which overlap with changes seen in conventional inflammatory bowel disease (IBD).1Nature Communications. Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis
The gut microbiome also plays a role. Patients who go on to develop IO colitis tend to have a different microbial makeup before or during treatment compared to those who do not. Specifically, researchers have found lower levels of Bacteroidetes and butyrate-producing bacteria, and higher levels of Proteobacteria and Enterococcus, in the stool of patients who develop colitis.2Journal of Crohn’s and Colitis. DOP47 Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitis The implication is that certain gut environments may prime the immune system toward intestinal inflammation once the checkpoint brakes come off.3PubMed. Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis
How Common Is IO Colitis
The risk varies dramatically by drug type. A meta-analysis of solid tumor patients found that ipilimumab (a CTLA-4 inhibitor) caused colitis in about 9 percent of patients overall, with roughly 7 percent developing severe colitis. PD-1 or PD-L1 inhibitors had much lower rates, around 1.3 percent for all-grade colitis and under 1 percent for severe cases. The highest risk comes from combination therapy using both ipilimumab and a PD-1 inhibitor together, which pushed all-grade colitis rates to about 14 percent and severe colitis close to 9 percent.4PubMed Central. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
A large single-center study broadly echoed those numbers, reporting colitis in about 14.5 percent of patients on combination PD-1 plus CTLA-4 therapy and 3.5 percent on PD-1 alone. That study also highlighted important differences beyond frequency: combination-therapy colitis hit sooner (a median of about 6 weeks versus 26 weeks for PD-1 alone), tended to be more severe, and more often required high-dose steroids.5Journal for ImmunoTherapy of Cancer. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab A systematic review in the journal Gut confirmed the broad pattern: CTLA-4-associated gut side effects are frequent and can look a lot like IBD, while PD-1-related gut problems are less common and more varied in how they present.6Gut. Enterocolitis due to immune checkpoint inhibitors: a systematic review
Recognizing the Symptoms
Diarrhea is the hallmark symptom. It may be watery at first but can progress to include mucus or blood in the stool. Abdominal pain, cramping, fever, nausea, and vomiting can all accompany it.7PubMed Central. Immune checkpoint inhibitor-induced diarrhea and colitis: an overview The typical onset window is about 6 to 10 weeks after starting immunotherapy, though it can appear much earlier or much later.8PubMed Central. Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report One melanoma study recorded a median onset of 67 days, with a range stretching from 4 days to nearly two and a half years after the first dose.9PubMed. Evaluation of colitis induced by immune-checkpoint inhibitors therapy in melanoma patients by an overall grading scale
That wide window matters because patients and their oncologists need to stay alert for gut symptoms far beyond the initial treatment cycles. If you are on a PD-1 inhibitor and develop persistent diarrhea months into therapy, IO colitis should still be on the radar. The speed of escalation also varies: some patients go from loose stools to bloody diarrhea within days, while others simmer with mild symptoms for weeks before things worsen.
Grading Severity
Doctors grade IO colitis using the Common Terminology Criteria for Adverse Events (CTCAE), a standardized scale used across oncology.10PubMed Central. Checkpoint Inhibitor-Induced Colitis: An Update The grades break down roughly like this:
- Grade 1: Fewer than four extra stools per day above your baseline, with mild symptoms.
- Grade 2: Four to six extra stools per day, with abdominal pain or blood in the stool.
- Grade 3: Seven or more extra stools per day, incontinence, need for IV fluids, or inability to care for yourself.
- Grade 4: Life-threatening complications such as bowel perforation or hemodynamic collapse.
The CTCAE scale is useful but has limitations. A melanoma study found that most patients fell into grade 1 or 2 by CTCAE criteria, yet over 80 percent were classified as moderate or severe when assessed by a more comprehensive overall grading system that incorporated endoscopic and histological findings. Treatment intensity and time to resolution tracked better with the overall grade than with the CTCAE grade alone, suggesting that stool frequency by itself does not always capture how inflamed the colon actually is.9PubMed. Evaluation of colitis induced by immune-checkpoint inhibitors therapy in melanoma patients by an overall grading scale
How IO Colitis Is Diagnosed
The workup starts with ruling out infections that can mimic IO colitis. Blood and stool tests help confirm the diagnosis and exclude bacterial or parasitic causes. Guidelines specifically recommend checking for Clostridium difficile, because its symptoms closely resemble those of IO colitis, and missing an active infection while starting immunosuppressive treatment could be dangerous.11Trends in Molecular Medicine. What is IO Colitis? Symptoms and Treatment Options – Section: Diagnostics of ICI-associated colitis
For patients with grade 2 or higher symptoms, a colonoscopy with biopsies is generally recommended.12PubMed Central. Diagnosis and Management of Immune Checkpoint Inhibitor Colitis What doctors see through the scope can vary quite a bit. A study evaluating endoscopic findings reported that about 40 percent of patients had non-ulcerative inflammation, 23 percent had ulcerative inflammation, and 37 percent had a colon that looked macroscopically normal despite active disease on biopsy. Histology showed acute inflammation in roughly 60 percent, chronic inflammation in about 28 percent, and microscopic inflammation alone in about 12 percent.13Journal of Clinical Oncology. Disease outcomes in immune checkpoint inhibitor colitis: A study comparing initial endoscopic and histological presentation and treatment options. That large share of patients with a normal-looking colon but abnormal biopsies underscores why biopsies matter: you cannot always diagnose IO colitis by appearance alone.
Under the microscope, IO colitis overlaps considerably with IBD. Both can show crypt damage, inflammatory infiltrates, and erosions. An expert panel recommended that pathologists evaluate features including structural changes, neutrophils in the tissue lining and within crypts, crypt destruction, ulceration, and apoptotic bodies.14Journal for ImmunoTherapy of Cancer. Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis The key distinguishing feature is that IO colitis tends to show more neutrophilic (acute) inflammation without the chronic architectural distortion typical of longstanding IBD.15PubMed Central. Immune checkpoint inhibitor-induced colitis: A comprehensive review
First-Line Treatment With Steroids
Corticosteroids are the backbone of IO colitis treatment. Guidelines recommend starting systemic steroids at around 1 milligram per kilogram per day for grade 2 colitis, escalating to 1 to 2 milligrams per kilogram per day for grade 3 or 4.16Journal for ImmunoTherapy of Cancer. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis Once symptoms improve, the steroids are tapered gradually, often over several weeks. The checkpoint inhibitor itself is typically held during treatment for colitis, and whether it can be restarted depends on how severe the episode was and how the patient responds.
For milder or microscopic forms of IO colitis, budesonide, a locally acting steroid that is gentler on the rest of the body, has shown promise. A study found that remission rates for moderate IO colitis on budesonide alone were comparable to systemic steroids, with lower risks of infection and other steroid-related complications.17PubMed Central. Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer Separate research specifically looking at microscopic IO colitis found that first-line budesonide controlled symptoms effectively and allowed patients to continue their cancer immunotherapy longer, avoiding the systemic steroid side effects that can undermine cancer treatment.18PubMed Central. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
When Steroids Are Not Enough
Roughly a third of patients with moderate-to-severe IO colitis do not respond adequately to steroids, which is where biologic therapies enter the picture. The two most commonly used are infliximab (an anti-TNF antibody) and vedolizumab (a gut-selective anti-integrin antibody). Both achieve high remission rates, and the choice between them has been actively debated.
A two-center observational study found that clinical remission rates were nearly identical for infliximab and vedolizumab, around 88 to 89 percent. However, patients treated with vedolizumab had shorter steroid exposure (35 versus 50 days), fewer hospitalizations, and shorter hospital stays, while infliximab produced a faster initial response.19Journal for ImmunoTherapy of Cancer. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study A recent meta-analysis pooling six studies with over 600 patients reached a similar conclusion on remission but found that vedolizumab was associated with lower recurrence rates and shorter systemic steroid exposure compared to infliximab.20PubMed Central. Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-Analysis
Because vedolizumab targets only gut-homing immune cells rather than suppressing the immune system broadly, some oncologists prefer it when they want to minimize any interference with the anti-tumor immune response. But infliximab works faster, which matters when a patient is acutely ill. In practice, the decision often comes down to urgency and the treating team’s experience.
Emerging Therapies for Refractory Cases
A small but real fraction of patients fail steroids and biologics entirely. For these refractory cases, fecal microbiota transplantation (FMT), which involves transferring stool from a healthy donor into the patient’s gut, has emerged as an experimental rescue option. An early case series published in Nature Medicine reported the first successful uses of FMT for IO colitis that had not responded to standard treatment, with evidence that the transplant shifted the gut microbiome toward a healthier composition and increased regulatory T cells in the colon lining.21PubMed Central. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
A larger case series followed, treating 12 patients with grade 3 or 4 IO colitis that had failed both first-line steroids and second-line biologics. Ten of the twelve showed symptom improvement after FMT, and by the end of the study period, 11 of 12 had achieved clinical remission.22PubMed Central. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis Patient-reported outcomes from FMT recipients also showed substantial drops in diarrhea and abdominal bloating within 12 weeks, with a significant reduction in the proportion of patients reporting moderate-to-severe symptoms overall.23Journal of Clinical Oncology. Effect of fecal transplantation on patient reported outcomes after immune checkpoint inhibitor colitis
For the most extreme refractory cases, clinicians have had to get creative. A recent case report described a patient whose IO colitis failed steroids, infliximab, vedolizumab, and a JAK inhibitor (upadacitinib), ultimately requiring a combination of JAK inhibition, therapeutic plasma exchange, and FMT to achieve resolution.24PubMed Central. Refractory Immune Checkpoint Inhibitor Colitis Treated With Biologics, Janus Kinase Inhibition, Plasma Exchange, and Fecal Microbiota Transplantation These are last-resort measures, but they illustrate how far the field has come in keeping options open when standard treatments fail. Rare but serious complications like bowel perforation can also occur, particularly in fulminant cases, sometimes requiring emergency surgery.25PubMed Central. Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease
Restarting Immunotherapy After IO Colitis
One of the trickiest decisions for oncologists is whether to restart the checkpoint inhibitor after IO colitis resolves. The cancer still needs treating, but the immune system has already shown it is willing to attack the gut. Data from a large pharmacovigilance analysis found that colitis had one of the higher recurrence rates among immune-related side effects when patients were rechallenged, at about 39 percent.26PubMed Central. Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals A separate study from JAMA Oncology confirmed that colitis was significantly more likely to recur on rechallenge than many other immune-related side effects, and that CTLA-4 regimens in particular carried a higher risk of recurrence.27JAMA Oncology. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
That said, overall rechallenge data across immune-related side effects are somewhat reassuring: while roughly a third to three-quarters of rechallenged patients experience some form of repeat event, fewer than a third of those are high-grade, and the second episode is unlikely to be more severe than the first.28PubMed Central. Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity Switching drug class (for example, from combination CTLA-4/PD-1 therapy to PD-1 alone) is a common strategy to maintain anti-tumor activity while lowering the risk of a colitis flare. These decisions are highly individualized, balancing cancer prognosis, severity of the initial colitis episode, availability of alternative treatments, and the patient’s own preferences.
IO Colitis and Cancer Outcomes
An interesting and somewhat counterintuitive finding is that patients who develop IO colitis may actually have better cancer outcomes than those who do not. A study published in World Journal of Gastroenterology found that patients who developed IO colitis had a longer average overall survival, about 24 months compared to roughly 18 months in matched controls who did not develop colitis.29PubMed Central. Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival The likely explanation is straightforward: if the immune system is revved up enough to attack the gut, it is probably also doing a better job of attacking the tumor. This association has been reported for several immune-related side effects beyond colitis and is one reason oncologists are reluctant to permanently stop immunotherapy after a manageable episode.
Predicting Who Will Get IO Colitis
Efforts to identify patients at risk before symptoms start are ongoing but still early. No blood-based biomarker has been validated for routine use to predict IO colitis in asymptomatic patients. However, stool markers like calprotectin are used as non-invasive indicators to monitor for colitis and track treatment response, potentially reducing the need for repeated colonoscopies.30PubMed Central. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
On the research front, one promising approach identified a 16-gene signature in blood samples drawn 30 days after starting a CTLA-4 inhibitor that could distinguish patients who went on to develop significant colitis from those who did not. In validation testing, the signature had reasonable discriminatory ability, though its sensitivity was modest, catching just over half of the cases that eventually developed.31PubMed Central. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab The microbiome itself is also being explored as a predictive tool: having more Bacteroidetes in your gut appears to be protective, while a microbiome rich in Firmicutes like Faecalibacterium correlates with higher risk.30PubMed Central. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events None of these tools are ready for routine clinical use yet, but they point toward a future where risk stratification could allow earlier intervention or even preventive strategies.